Introduction
============

Leukemic transformation of Ph-negative myeloproliferative neoplasms (MPN; polycythemia vera, PV; essential thrombocythemia, ET; primary myelofibrosis, PMF) is a relatively rare but fatal event. Several intrinsic risk factors have been suggested involving MPN phenotype (PMF\>PV\>ET), abnormal karyotype and higher age.^[@bib1]^ The effect of MPN therapy has been widely discussed and alkylating agents, pipobroman and ^32^P were shown to be leukemogenic.^[@bib1],\ [@bib2],\ [@bib3]^ Possible negative impacts of hydroxyurea (HU) remain controversial,^[@bib1],\ [@bib2],\ [@bib4],\ [@bib5],\ [@bib6],\ [@bib7],\ [@bib8],\ [@bib9]^ as summarized in.^[@bib10]^ Great effort has been invested into the search for genetic changes predicting and/or triggering MPN transformation to AML and MDS.^[@bib11],\ [@bib12],\ [@bib13],\ [@bib14],\ [@bib15],\ [@bib16]^

Eliminating tumor suppressor *TP53* during myelopoiesis helps escape from control mechanisms preventing differentiation loss, aberrant self-renewal, and large genome rearrangements.^[@bib17],\ [@bib18]^ In chronic MPN phase, *TP53* gene defects have been extremely rarely detected using Sanger sequencing or cytogenetic analysis; on the contrary, they were shown to be common in post-MPN acute myeloid leukemia (AML).^[@bib19],\ [@bib20],\ [@bib21]^ This pronounced difference is indicative of *TP53* role in the transformation process. Retrospective analysis of individual cases of *TP53*-mutated post-MPN AML showed that *TP53* mutations can be traced months or even years before leukemic transformation.^[@bib11],\ [@bib19],\ [@bib22],\ [@bib23]^ The level of mutation burden was shown to remain low until complete p53 inactivation by losing the second allele (17p defects or second mutation), followed by rapid clonal expansion.^[@bib11],\ [@bib22]^

*TP53* mutations occurring at a level above detection limit of Sanger sequencing (10--20% variant allelic frequency; VAF) show negative prognostic and/or predictive impact in some types of cancer, especially in hematological malignancies.^[@bib24],\ [@bib25]^ Small *TP53*-mutated subclones below this sensitivity threshold were described to drive relapse or disease progression in many cases of chronic hematological malignancies,^[@bib26],\ [@bib27],\ [@bib28],\ [@bib29]^ but their impact is less clear in prospective setting.^[@bib30]^ Cytotoxic agents support a minor *TP53*-mutated subclone overgrowth.^[@bib26],\ [@bib31],\ [@bib32],\ [@bib33]^ Previous therapy with hydroxyurea (HU), a ribonucleotide reductase inhibitor activating p53 response via replication stress,^[@bib34],\ [@bib35]^ has been associated with *TP53*/17p defects in post-MPN AML;^[@bib4],\ [@bib12],\ [@bib22],\ [@bib36]^ however, this observation has not been confirmed in a large unbiased study.

While minor *TP53* mutations in MPN have been tracked retrospectively in individual cases and have been suggested as carrying an increased risk of leukemic transformation,^[@bib11]^ the occurrence of low-burden *TP53* mutations (\<5%) has not been analyzed so far. Whether therapy or other factors affect their origin and outgrowth is unknown. To map *TP53*-mutated subclones\' presence in MPN patients treated with cytoreductive drugs and study their evolution over time, we used an ultra-deep next-generation sequencing (NGS) approach.

Patients and methods
====================

Patients and samples
--------------------

Peripheral blood (PB) samples and clinical and routine laboratory data from MPN patients were collected from Czech hospitals (University Hospital Brno and local hospitals) and Vienna General Hospital, Austria. The study was approved by the Ethical Committee of University Hospital Brno. For all samples, written informed consent approved by the Ethics Committees of the respective institutions were available in accordance with the Declaration of Helsinki. Patients were diagnosed according to the revised World Health Organization criteria.^[@bib37]^

In total, 339 MPN patients were included ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). Treated patients (*N*=254) were having or had discontinued cytoreductive therapy--HU, interferon alpha-2a (IFN) or anagrelide (ANG)---and had been diagnosed ⩾4 years (y) before sampling. To assess the effect of therapy, the treated patients were categorized as follows: (1) by administration of HU, IFN or ANG at any time during disease course (referred to as HU-yes/HU-no, IFN-yes/IFN-no, ANG-yes/ANG-no); (2) more strictly, in the HU-yes group, only patients fulfilling a criterion of HU treatment for ⩾4y were kept. This group was compared to HU-no patients. Besides these, 85 samples from patients with no cytoreductive therapy before sampling were analyzed. Retrospective and prospective samples from 31/50 patients with detected *TP53* mutations were analyzed to describe mutation development.

Ultra-deep next-generation sequencing of *TP53* amplicons
---------------------------------------------------------

NGS analysis was performed as described previously^[@bib26]^ with minor modifications. Briefly, 30 ng of leukocyte or granulocyte DNA was amplified with high-fidelity Q5 Polymerase (New England Biolabs, Ipswich, MA, USA) using primers specific for the *TP53* exons 4--10. The indexed library was prepared with Nextera XT DNA Sample Preparation Kit (Illumina, San Diego, CA, USA) and sequenced using MiSeq Reagent Kit v2 (300 cycles; Illumina, San Diego, CA, USA) on a MiSeq instrument according to manufacturer recommendations. The coverage per base exceeded 5000 (⩾10 000 in 82% of exons); mean coverage reached 39535. For variant detection we used bioinformatics pipeline ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}) combining CLC Genomic Workbench version 7.5 (Qiagen, Hilden, Germany) and the deepSNV R-package.^[@bib38],\ [@bib39],\ [@bib40],\ [@bib41],\ [@bib42]^ Samples containing variants above 0.2% VAF by either approach were subjected to validation from independent sampling and/or PCR amplification ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}). For over-time monitoring and validation of previously identified mutation, cutoff 0.1% was applied (minimal coverage per base ⩾10 000).

Statistical analysis
--------------------

Statistical analyses were performed within the R environment.^[@bib42]^ The distribution normality was tested using the Kolmogorov-Smirnov normality test. Non-parametric tests were applied because of normality violation in most clinical variables (for example, age distribution). To analyze the relationship between the variables, the Spearman correlation test, Mann--Whitney test, Kruskal--Wallis test and Fisher's exact test with simulated *P*-value (Monte-Carlo simulation) were used. Data sets were described with median and s.d. and/or range as indicated in the legends. The comparison of patients\' survival was performed by log-rank test and visualized using Kaplan--Meier curves; Cox proportional hazards regression was used to model the effect of multiple predictor variables. Logistic regression models were applied to assess the significance of age and therapy in *TP53* mutational status. Age adjustment was performed by adding the age covariate into the logistic model. Finally, the age-adjusted models were compared with a model with age parameter only by anova chi-square tests. The level of statistical significance was set *P*⩽0.05. All statistical tests were performed as two-sided. Plots were created with the GraphPad Prism version 5.00 for Windows (GraphPad Software, La Jolla, CA, USA).

Single-nucleotide polymorphism arrays
-------------------------------------

Genome-wide analysis was performed on CytoScan HD arrays (Affymetrix, Santa Clara, CA, USA) according to the manufacturer\'s instructions. CEL files were analyzed using the Chromosome Analysis Suite software, v3.1.0.15 (Affymetrix, Santa Clara, CA, USA) and annotated using NetAffx 33.1 annotation data set.

For details on methods see [Supplementary Material](#sup1){ref-type="supplementary-material"}.

Results
=======

Ultra-deep NGS analysis of *TP53* gene in treated MPN patients
--------------------------------------------------------------

To screen for *TP53* mutations and assess the effect of therapy, we analyzed 254 chronic-phase MPN patients using ultra-deep NGS. All patients were treated with one or more cytoreductive drugs (hydroxyurea, HU; interferon alpha-2a, IFN; anagrelide, ANG) and diagnosed ⩾4y before sampling (4.2--29.5; median 9.2y; [Supplementary Table S1](#sup1){ref-type="supplementary-material"}). *TP53* mutations were identified in 41 patients (41/254; 16.1% [Table 1](#tbl1){ref-type="table"}) with VAF for the most abundant variant ranging between 0.2 and 11.6%. In a pronounced proportion of patients, more than one mutation was present (11/41; 26.8%). Colony-forming assay^[@bib43],\ [@bib44]^ performed in 3 patients confirmed the presence of *TP53*-mutated subclones within *JAK2* or *CALR*-mutated populations ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}). To verify the mutations' presence in myeloid lineage in patients examined from leukocyte DNA, the granulocyte sample was analyzed where available. No evident discrepancy was found ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}).

*TP53* mutations in MPN are strongly associated with higher age
---------------------------------------------------------------

*TP53* mutations were found in all disease subtypes, regardless of driver gene status and even if no HU had been administered ([Figure 1](#fig1){ref-type="fig"}; [Table 2](#tbl2){ref-type="table"}). Further, we performed thorough analysis of relationships between *TP53* mutational status and disease parameters ([Supplementary Table S4](#sup1){ref-type="supplementary-material"}). The comparison of patients carrying *TP53* mutation (*TP53*-mut) to patients without *TP53* mutation (*TP53*-wt) revealed a highly significant association between *TP53* mutations and higher age (*P*=5.54 × 10^−5^; median age at sampling 69.3 for *TP53*-mut and 62.4 for *TP53*-wt; [Figure 2a](#fig2){ref-type="fig"}). *TP53* mutations were less frequent in patients who obtained ANG during disease course (9/104, 8.7% in ANG-no vs 32/150, 21.3% in ANG-yes; *P*=0.0087). Patients receiving HU at sampling carried the *TP53* mutation more frequently (HU at sampling, 28/125, 22.4% vs without HU at sampling, 13/128, 10.2% *P*=0.0205) but associating the *TP53* mutation with HU administration anytime during disease course did not reach significance (31/164; 18.9% in HU-yes vs 10/90; 11.1% in HU-no). As expected, the age at sampling was significantly associated to multiple therapy parameters, partially due to the frequent use of HU in older patients ([Figure 2b](#fig2){ref-type="fig"}, [Supplementary Figure S3](#sup1){ref-type="supplementary-material"}).

As the patient cohort was compiled of several hospitals\' contributions, which may have introduced bias, we limited the analysis to University Hospital Brno patients (*N*=169; N~*TP53*-mut~=22), which lead to similar results (data not shown).

Some of the patients received HU for a short time period and were switched to other therapy or vice versa. Thus, to further disclose the relationship between *TP53* mutations, HU, and age, we eliminated these patients from the analysis, using more stringent criteria to categorize patient therapy ([Figure 2c](#fig2){ref-type="fig"}; [Supplementary Table S5](#sup1){ref-type="supplementary-material"}): (1) patients who had obtained HU for at least 48 months (*N*=122) and (2) patients treated with IFN and/or ANG only (HU-no; *N*=90). Also in this subset, patient age was the most significant predictor of *TP53* mutation ([Supplementary Figure S4A](#sup1){ref-type="supplementary-material"}; *TP53*-mut 69.5y vs *TP53*-wt 63.4y; *P*=0.0009) and *TP53* mutations were more frequent in patients in the HU subgroup (HU⩾4y, 28/122, 22.9% vs HU-no, 10/90, 11.1% *P*=0.03). In parallel, the therapy category was strongly associated to age ([Supplementary Figure S4B](#sup1){ref-type="supplementary-material"}). To eliminate the influence of age, we applied a logistic regression model with the age adjustment ([Supplementary Table S6](#sup1){ref-type="supplementary-material"}); using this approach, the *TP53* mutation frequency was not found to be significantly different in patients treated with various cytoreductive drugs. This is in agreement with the observation that in patients over 65y, the difference in proportion of *TP53* mutation between HU⩾4y and HU-no therapy groups was much lower (23/75, 30.6% vs 6/30, 20.0% n.s.) even though the HU-no group was significantly younger (*P*=0.026; [Supplementary Figure S5](#sup1){ref-type="supplementary-material"}).

To further explore whether minor *TP53* mutations occur independently of the therapy, we examined a set of 85 patients with no cytoreductive treatment ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}) and found *TP53* mutations in 9 of them (10.6% [Supplementary Table S7](#sup1){ref-type="supplementary-material"}, [Supplementary Figure S6](#sup1){ref-type="supplementary-material"}).

*TP53* mutations in HU-treated and other patients
-------------------------------------------------

We did not see any difference in mutation spectra between patients treated with HU and the others ([Supplementary Figure S7](#sup1){ref-type="supplementary-material"}). Neither the VAF of the most abundant variant nor the cumulative size of the mutated population significantly differed between the therapy groups ([Figure 3](#fig3){ref-type="fig"}). Nevertheless, we observed a trend towards the presence of more than one mutation (⩾0.2% VAF) in HU-treated patients (10/31) compared to patients treated with non-HU drugs (1/10) and untreated patients (2/9) (n.s.). The mutations showed typical distribution, the vast majority of them were located within the DNA-binding domain and they clustered within characteristic hot-spot sites ([Supplementary Figure S8](#sup1){ref-type="supplementary-material"}, [Supplementary Table S8](#sup1){ref-type="supplementary-material"}). All but one patient carried mutations which have been described as non-functional or, rarely, partially functional. The exception was the mutation p.P58A (MP189; VAF 2.9%) which displays no significant loss of transactivation activity.^[@bib45],\ [@bib46]^ The mutation remained stable in all three samplings (7.7y). We have not excluded the mutation from the analysis as we could not rule out other effects on p53 function.

*TP53* mutations may escape detection if examined at diagnosis
--------------------------------------------------------------

Since the majority of mutations we describe were identified in samples taken later during the disease course, we raised the question whether the mutations can be detected earlier, or even at diagnosis. Out of 50 patients with a mutated clone, at least one retrospective sample was available in 20 ([Table 2](#tbl2){ref-type="table"}). A later identified mutation was traceable in at least one sample in 14 patients. The sample from the time of diagnosis was available in 10 patients; no *TP53* mutation was detected in 5 (50% VAF⩾0.1%) of them. Correspondingly, the mutation was detectable at diagnosis in only one of two patients who later developed *TP53*^mut^ sAML (JAK22 and JAK453; [Figure 4](#fig4){ref-type="fig"}). In conclusion, despite some *TP53* mutations being found at diagnosis with VAF⩾10% (JAK646: 16.3%, [Supplementary Table S7](#sup1){ref-type="supplementary-material"}; 221A: 10.2% [Table 3](#tbl3){ref-type="table"}), mutations frequently appear later in the disease course and may be undetectable (⩾0.1%) at diagnosis.

Monitoring patients with *TP53* mutations -- dynamic behavior of mutated clones
-------------------------------------------------------------------------------

To explore *TP53* mutation evolution in MPN prospectively, disease course was monitored and serial samples were collected. Prospective samples were available in 30 of 50 MPN patients with *TP53*^mut^-subclones (median between study enrollment and the last serial sample 2.8y; 0.5--9.6y; [Table 3](#tbl3){ref-type="table"}). *TP53* mutations remained present in all but three serial samples (MP63, MP160 and MP307) in which mutations originally identified and confirmed in 0.2% were not detected 3.4, 2 and 1.6 years later, respectively.

*TP53* mutation expanded and became predominant tumor cell population in 2/30 patients. The expansion was accompanied by the second allele inactivation in both cases. While the JAK22 patient progressed to AML carrying biallelic *TP53* inactivation (VAF 46%), the clonal biallelic expansion in patient MP10 (VAF 86%) did not result in leukemic transformation; this case is described further in detail ([Figure 4](#fig4){ref-type="fig"}; [Supplementary Table S9](#sup1){ref-type="supplementary-material"}).

When we considered all samples tested during the disease course, that is, retrospective as well as prospective samples, median interval between first and last sample was 7.1y (0.5--24.6; 31 patients). During this time, a slow mutation burden increase was the most frequent scenario (14 patients). We saw no clear association between the mutation burden changes and the VAF at study enrollment, therapy, other clinical data or mutation localization ([Table 3](#tbl3){ref-type="table"}, [Supplementary Figure S8B](#sup1){ref-type="supplementary-material"} and [S10](#sup1){ref-type="supplementary-material"}).

Impact of *TP53* mutations on overall survival or leukemic transformation
-------------------------------------------------------------------------

*TP53* mutation with VAF\<5% did not impact overall survival (OS) during the follow-up when tested either from diagnosis or study enrollment ([Supplementary Figure S9](#sup1){ref-type="supplementary-material"}). The patients carrying *TP53* mutations above 5% VAF at study enrollment had significantly shorter OS (*P*=0.0064 OS from sampling, *P*=0.0185 OS from diagnosis). However, the impact on OS was lost when adjusted for age (Cox proportional hazard regression model for both age and mutation: *P*=1.01 × 10^−10^ for age; *P*=0.121 for *TP53* mutation\>5%). Besides, their shortened survival was not attributed to *TP53*-mut AML ([Supplementary Figure S9G](#sup1){ref-type="supplementary-material"}).

In total, AML developed in three patients with *TP53* mutation (3/50; 6% [Figure 4](#fig4){ref-type="fig"}). Patient JAK22 (p.289fs 2%) was diagnosed with PV 4y after chemo/radiotherapy for B-cell lymphoma. The patient was treated with HU and progressed to *TP53*^mut^-AML 5y later. On the contrary, patient MP68 (p.R248Q 6.9%) treated with HU developed *JAK2*^wt^*TP53*^wt^-AML outside multiple *JAK2*^mut^*TP53*^mut^-clones 3.5y from study enrollment (8.3y from diagnosis). Patient 186A (p.P153fs 8.27%) treated with IFN progressed to AML 2.9y after mutation detection (17.9y from diagnosis). The patient was switched to HU soon after study enrollment and an AML sample was not available, thus we cannot confirm the clonal expansion of *TP53* mutation or the effect of the therapy.

Rapid *TP53*-mutated clone expansion accompanied by cn-LOH but no other karyotype changes resulted neither in AML transformation nor HU resistance
--------------------------------------------------------------------------------------------------------------------------------------------------

In the *JAK2*^mut^-PMF patient MP10, multiple *TP53* low-burden mutations were present at study enrollment. Among them, a hot-spot *TP53*^G245S^ mutation grew rapidly during prospective monitoring up to 95% in granulocytes ([Figure 4](#fig4){ref-type="fig"}), reflecting the loss of heterozygosity (LOH). Since complex karyotype changes have been described as very common in AML with mutated *TP53*,^[@bib18]^ we analyzed the karyotype changes using CytoScan HD arrays. Only copy-neutral LOH (cn-LOH) in 17p13, including *TP53* gene, and chromosome Y loss were detected in the expanded clone. To further examine the time course of allelic changes, we analyzed myeloid progenitors. CFC assay indicated that second allele inactivation occurred intra-clonally in the clone carrying monoallelic p.G245S mutation ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}). Interestingly, despite complete p53 inactivation and clonal expansion, the patient remained clinically stable without signs of blast transformation for next 23 months, showed no signs of HU resistance and died 10.2y from diagnosis.

Discussion
==========

Previously published retrospectively analyzed cases showed that the development of *TP53*-mutated post-MPN AML is a multistep process. It likely involves mutation origin in the HSPC pool, mutated subclone propagation to level exceeding detection limit and persistence at low levels for an extended time period. Second allele inactivation was described as resulting in rapid clonal expansion and leukemic transformation.

We focused on the early phase of this process, that is, occurrence of low-burden *TP53* mutations which, in theory, may carry increased risk of leukemic transformation. Using highly sensitive and previously verified methods enabled us to detect mutations as low as 0.2%.^[@bib26]^ In total, we found mutations in 50 patients (14.7%). This is the first study using ultra-deep NGS to search for *TP53* mutations in MPN at a level ⩽1%. Lundberg et al.^[@bib11]^ found mutations in 5/197 (2.5%) patients using NGS with sensitivity of 5%, which roughly corresponds to our data (5 patients with mutations \>5% out of all 339 examined, 1.5%). As our study aimed to compare patients on HU and non-HU therapies, the frequency in the general MPN cohort was out of the scope. However, some information may be gained from our analysis of 48 consecutive newly diagnosed MPNs examined partially within the untreated cohort and partially as retrospective samples (data not shown): only one mutation ⩾0.2% was found (2.1%). This observation, together with the slow increase in mutation load during disease course and strong age bias, points to the fact that *TP53* mutations are probably rare in general cohorts at diagnosis.

We detected no mutation ⩾0.2% in 70 patients below 55y. In contrast, 41/179 (22.9%) patients above 65y carried *TP53* mutation. This agrees with the hypothesis that *TP53* mutations arose spontaneously and accumulate with age, as described in the elderly population without hematological abnormalities.^[@bib47]^ Higher age brings inherent risks of MPN transformation^[@bib1]^ and less vital progenitor pools in the elderly may favor cells carrying oncogenic mutations both under DNA-damaging and normal conditions.^[@bib48]^ On the other hand, younger patients are a subgroup with the perspective of decades living with clonally shifted hematopoiesis and using cytoreductive drugs and should be examined in detail.

It has been described that not only single accidentally arising *TP53*-mutated clones but several coexisting in parallel may be present in myeloid precursors before expansion.^[@bib49]^ We detected more than one mutation in one third of cases. This phenomenon, described as 'convergence',^[@bib50]^ occurs for example, in chronic lymphocytic leukemia (CLL)^[@bib51]^ and points to a selective pressure favoring the mutations in some but not all patients. In MPN, one may consider either the pressure of cytoreductive therapy, since multiple mutations tended to be more frequent in HU-treated patients, or, possibly, the effort of non-vital HPSC to survive and proliferate. The clonal competition among individual *TP53*-mutated subclones is difficult to foresee and likely depends on accompanying defects; hot-spot mutations with documented oncogenic properties may be overgrown by subclones carrying variants with lower oncogenic potential (for example, loss-of function mutations).^[@bib25],\ [@bib26]^

The murine model and clinical observations pointed to the leukemogenic potential of *JAK2*^V617F^ overexpression in *TP53*-null background;^[@bib23],\ [@bib52]^ *JAK2*^wt^*TP53*^mut^ AML following *JAK2*^mut^-MPN is however not exceptional.^[@bib22]^ We observed no clear evidence supporting the leukemogenic potential of *TP53*^mut^ and *JAK2*^V617F^ combination. Admittedly, the *JAK2* mutation was homozygous neither in patient MP68 developing *JAK2*^wt^-AML alongside multiple *JAK2*^mut^*TP53*^mut^ subclones nor patient MP10 with complete *TP53* loss within the *JAK2*^V617F^ population.

*TP53*/17p-aberrant post-MPN AML has been repeatedly suggested - but never independently proven - to be associated with HU therapy.^[@bib4],\ [@bib12],\ [@bib22],\ [@bib36]^ Several findings support possible *TP53*^mut^-subclone selection by HU: (1) HU blocks cell division via ribonucleotide reductase inhibition, resulting in dNTP depletion.^[@bib34]^ Replication stress then activates p53 and cell cycle arrest although these processes\' p53 dependence is controversial and dose-dependent.^[@bib35],\ [@bib53],\ [@bib54]^ (2) The expansion of low-burden *TP53*^mut^-subclones under *TP53*-triggering therapy was shown in CLL,^[@bib26],\ [@bib27],\ [@bib28]^ myelodysplastic syndrome^[@bib29]^ and secondary AML.^[@bib32]^ Further, HSPC competition triggered by low-level DNA damage in the murine model led to *TP53*^+/+^ being outcompeted by *TP53*^+/-^ cells via senescence-like changes.^[@bib33]^ Similarly, clinically relevant low- (but not high) level replication stress induced p53-dependent senescence-like arrest in fibroblasts and led to *TP53*-aberant subpopulation selection.^[@bib53]^ We suppose that if there was a proliferative and/or survival advantage favoring *TP53*^mut^-subclones during HU treatment in MPN, we would have observed a pronounced difference in the abundance and incidence of low-burden *TP53* mutations after several years of therapy. Contrary to this assumption and observations from *in vitro* and *in vivo* models, we saw no significant age-independent difference between patients treated with HU and non-HU therapies; moreover, the mutations were present even if no cytoreductive therapy was given. Although long-term prospective monitoring of patients with *TP53* mutations on various therapies is necessary to fully exclude any HU impact on the second allele loss and clonal expansion, the case of patient MP10 further weakens the advantage of MPN cells with aberrant p53 during HU therapy. While the *TP53*^G245S/G245S^ clone replaced *TP53*^wt^ myelopoiesis, the patient did not show any signs of HU resistance, blood counts remained unchanged and no disease progression was observed for next 2y, despite the patient being treated with a constant HU dose. The clonal competition in MPN both under and without HU treatment may differ from experimental data for several reasons: (1) chronic low-level replication stress may affect HPSC compartment differently to single dose DNA damage; (2) in highly sensitive myeloid cells, threshold for p53-dependent selection induced by low-level replication stress^[@bib55]^ may be shifted; (3) competition may be affected by presence of oncogenic mutations; (4) p53 activity in MPN cells may not fully correspond to that of artificially manipulated p53 in murine and cell line models. In contrast, there seems to be a difference between subclones with monoallelic and biallelic p53 defects, first increasing slowly with the latter expanding rapidly.^[@bib11]^

We showed that relatively high proportion of older-age MPN patients carry low-burden *TP53* mutations. In contrast to retrospective reports, we did not observe correlation with disease progression accompanied with *TP53* mutation clonal expansion. However, our study was not designed with the primary goal to assess the prognostic impact of low-burden *TP53* mutations as we were aware that larger cohorts and long follow-up is definitely required to address this issue completely.

The competition between an in-theory-adverse minor subclone and a major population may be more complex than one may assume from the retrospective studies. Observations on minor *TP53* mutations in CLL, another non-acute hematological malignancy, show that the mutation does not have to expand despite several specific therapy lines in some patients.^[@bib26]^ Further, a *TP53*-mutated subclone outgrowth occurs very rarely in patients that remain untreated, that is, strong selection pressure in the form of chemotherapy dramatically changes the *TP53*-wt vs *TP53*-mut clonal competition.^[@bib26],\ [@bib28]^ Apparently, cytoreduction regimens currently used in MPN do not create such strong pressure. More likely, other intrinsic factors (genomic instability, hematopoiesis exhaustion) lead to disease progression only in a proportion of patients carrying minor *TP53*-mutated clone.

Importantly, 3 out of 4 patients with clonal evolution (blast transformation or mut-*TP53* clonal expansion) carried *TP53* mutation(s) with VAF⩾5%. This indicates that *TP53* mutations increased to a certain level may be the marker of clonal instability or even a poor prognosis, as demonstrated by shorter OS in patients with mutations ⩾5% VAF in our study which however cannot be attributed to *TP53* mutation expansion followed by leukemic transformation. Of note, we recorded 6 patients whose prospective samples were available and VAF exceeded 5% at some point, but none developed *TP53*-mutated sAML during the follow-up. Moreover, one patient with no mutations ⩾0.1% VAF developed *TP53*-mutated sAML within 3.6y.

To conclude, we show that minor *TP53* mutations are present in a significant proportion of MPN patients and their presence is strongly associated with age. We did not see any significant age-independent association with hydroxyurea therapy, disease type or MPN driver gene mutations. We also show that even a fully expanded biallelic hotspot mutation, leading to complete loss of *TP53* transactivation activity,^[@bib45],\ [@bib46]^ does not *a priori* lead to leukemic transformation. Despite our findings do not support the assumption that there is unequivocal relation between *TP53*-mutated subclones, HU cytoreduction and leukemic transformation in MPN, larger sample sizes are warranted to definitively address this. *TP53* minor mutations in MPN undoubtedly represent a pool for further clonal evolution; however their prognostic and predictive utilization requires further investigation to identify which patients are at risk and whether any risk factors are preventable.
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![Disease type and driver gene mutation status stratified according to *TP53* mutation presence in patients treated with cytoreductive drugs (NS; Fisher exact test). Driver gene mutations examined in order of *JAK2*\>*CALR*\>*MPL*.](leu2017230f1){#fig1}

![TP53 mutations: age and treatment in patients treated with cytoreductive drugs. (**a**) Age at sampling in *TP53*-mut and *TP53*-wt patients (*P*=5.54 × 10^−5^; Kruskal--Wallis test). (**b**) Age at sampling and *TP53* mutation frequency according to therapy parameters (Kruskal--Wallis and Fisher exact test, respectively; age: HU-yes/no *P*=0.0007; HU at sampling yes/no *P*=3.96 × 10^−7^; ANG-yes/no *P*=1.32 × 10^−8^; IFN-yes/no *P*=0.0006; multiple therapies during disease course yes/no *P*=8.7 × 10^−8^). Lines within boxes indicate median, box limits---25th and 75th percentiles, whiskers---minimum and maximum. (**c**) Comparison of patients treated with HU for ⩾4y and patients treated with IFN or/and ANG only. (i) Relationship between clinical and laboratory parameters. Red boxes: significant, scaled from *P*⩽0.0001 (dark red) to 0.05⩾*P*\>0.01 (light red). Statistical tests used for combinations of variables: continuous---Spearman correlation test, continuous vs categorical---Kruskal--Wallis test; categorical--Fisher's exact test. (ii) Logistic regression model with the age adjustment did not reveal any age-independent significant difference. \*Multiple therapies=more types of cytoreductive therapy during disease course. Length of the therapy=restricted to patients positive for given therapy type.](leu2017230f2){#fig2}

![Mutated clone size. VAFs of most abundant mutation and VAF sums do not significantly differ between therapy groups (Mann--Whitney test).](leu2017230f3){#fig3}

![Selected cases of leukemic transformation or clonal expansion in patients with *TP53* mutations. Details on cytogenetic analysis using Single-nucleotide polymorphism (SNP) HD Array are shown in [Supplementary Table S9](#sup1){ref-type="supplementary-material"}. MP10: *TP53*^G245S^ clonal expansion without leukemic transformation in PMF. *TP53*^G245S^ development was monitored by Sanger sequencing. Diagnostic sample and two other samples (green and purple mark) were analyzed by NGS, for detail see [Supplementary Table 1](#sup1){ref-type="supplementary-material"}. Chromosome 17 analysis: cn-LOH(17)(p13.3p11.2) in 2nd and 3rd SNP array. MP68: *JAK2*^wt^*TP53*^wt^-AML outside multiple *JAK2*^V617F^*TP53*^mut^-clones. After transient increase of *JAK2*^V617F/wt^*TP53*^R248Q^ subclone from 8 to 16%, all *TP53*^mut^ clones decreased accompanied by *JAK2*^V617F^ burden drop and transformation to sAML 3.5y from study enrollment. SNP array showed no aberrations on chromosome 17. JAK22: *JAK2*^V617F^*TP53*^L289fs/L289fs^ sAML with complex karyotype changes including cn-LOH(17)(p13.3p11.2) developed from PV secondary to diffuse large B-cell lymphoma (DLBCL). Single mutation *TP53*^L289fs^ was present at PV diagnosis (2%) and expanded in blast transformation. 186A: sAML with unknown *TP53* status developed in *JAK2*^mut^ ET 2.9y after study enrollment when *TP53* mutation was present with VAF 8.3%. JAK453: *JAK2*^V617F^*TP53*^R175H/-^ sAML with complex karyotype changes including del(17p) developed 3.6y after study enrollment at PMF diagnosis when no *TP53* mutation and karyotype changes were found.](leu2017230f4){#fig4}

###### Clinical and laboratory data of patients treated with cytoreductive drugs and carrying *TP53* mutations

                       *Disease type and course*   *Therapy*   *Mutations*   *Follow-up*                                                                                                                               
  --------- --------- --------------------------- ----------- ------------- ------------- ----- ----- ---- ----- ----- ----- ---- ------ ----------------------------------------------------------------------- ----- -------------------------------------------
    no HU     MP315              JAK2                  M           PV            62        109   89    I     0     0     0    no   0.8                                p.Y126D 0.79                                39                      Alive
              048C               JAK2                  M           PV            73        145   96    I     0    96     0    no   0.8                                p.E285K 0.82                                41                      Alive
             JAK1716             JAK2                  F           PV            63        111   110   I     0    110    0    no   0.2                                p.C238S 0.20                                83                      Alive
              MP189            CALR+JAK2               F           ET            67        138   112   A     0     0    112   no   2.9                                 p.P58A 2.90                                51                      Alive
              MP247              CALR                  F           PMF           56        122   119   A     0     5    115   no   0.3                                p.Y220C 0.26                                48                      Alive
              MP155              CALR                  F           PMF           61        122   121   A     0     0    121   no   0.2                                p.V143E 0.21                                52                      Alive
              227A               CALR                  M           PMF           72        154   123   I     0    123    0    CH   0.3                                p.A138V 0.26                                10                      Dead
               65A               CALR                  F           ET            70        158   152   IA    0    152   11    no   1.7                        c.376-2A\>G 1.71; p.R273H 0.2                       121                     Alive
              186A               JAK2                  F           ET            80        180   175   I     0    175    0    no   8.3                               c.454dupC 8.27                               37       Dead-AML[b](#t1-fn3){ref-type="fn"}
              221A               CALR                  M           ET            69        180   179   I     0    179    0    no   2.2                                p.I162S 2.24                                118                     Alive
   HU \<4y    MP15               JAK2                  M           PV            66        84    84    I    17    77     0    no   4.4                                 p.Y220C 4.4                                62                      Alive
              MP160              JAK2                  M           ET            69        61    18    H    18     0     0    no   0.2                                p.P142R 0.23                                52                      Alive
              MP68               JAK2                  F           MPN           70        58    56    H    47     0     9    no   6.9    p.R248Q 6.90; p.A159V 6.40; p.P151R 1.73; p.I195S 0.24; p.R273H 0.23    44       Dead-AML[c](#t1-fn4){ref-type="fn"}
   HU ⩾4y     MP326              JAK2                  F           PV            58        80    48    H    48     0     0    no   0.6                                p.Y220C 0.55                                39                      Alive
              MP345              JAK2                  M           PV            68        50    48    H    48     0     0    no   1.1                                p.S215R 1.10                                38                      Alive
              MP302              JAK2                  F           PV            71        231   65    H    56     0     0    B    0.4                                p.G199E 0.44                                29                      Alive
              MP319              JAK2                  M           PV            61        62    57    HA   57     0    32    no   0.4                                p.R273H 0.37                                28                      Alive
              MP168              JAK2                  F           PV            68        86    57    H    57     0     0    no   1.0                                p.H179R 0.95                                49                      Alive
              MP153              JAK2                  M           PV            63        62    61    HA   60     0    61    no   0.2                                p.R213G 0.23                                51                      Alive
              MP96               JAK2                  F           PV            55        64    62    H    62     0     0    no   0.5                         p.I195T 0.51; p.R282W 0.20                         54                      Alive
              MP327              JAK2                  F           ET            73        125   64    H    64     0     0    no   0.5                                p.R273H 0.47                                39                      Alive
              MP317              CALR                  M           PMF           81        65    65    H    65     0     0    no   0.8                         p.V216M 0.83; p.H179R 0.25                         17                      Dead
              MP63               JAK2                  F           ET            68        79    69    H    69     0     0    no   0.2                                p.M246V 0.20                                53                      Alive
               MP5               JAK2                  M           PV            68        70    70    H    70     0     0    no   0.3                                p.I195T 0.26                                64                      Alive
              MP10               JAK2                  M           PMF           79        77    76    H    76     0     0    no   10.5   p.G245S 10.50; p.R158H 0.54; p.H168R 0.29; p.F134L 0.23; p.Y234H 0.21   46    Dead-expansion[d](#t1-fn5){ref-type="fn"}
              MP307               MPL                  F           PV            82        103   76    H    76     0     0    no   0.2                              c.572_574del 0.21                             40                      Alive
              MP369              JAK2                  F           PV            73        84    81    H    81     0     0    no   1.4                                p.T170M 1.39                                35                      Alive
              MP246              JAK2                  F           ET            71        108   103   A    82     0    30    no   0.2                          p.D259H 0.2; p.G245S 0.2                          48                      Alive
              MP314              JAK2                  F           PV            69        233   92    H    86     0     0    B    1.3                         p.C242Y 1.26; p.G245D 0.35                         39                      Alive
               MP8               JAK2                  M           PV            82        92    90    H    90     0     0    no   0.2                                p.R175H 0.24                                49                      Dead
              MP356              JAK2                  F           ET            69        109   91    H    91     0     0    no   1.6                                p.R248Q 1.64                                37                      Alive
              MP230              JAK2                  M           MPN           70        96    96    H    96     0     0    no   0.5                p.R248Q 0.50; c.512_514dup 0.22; p.V274G 0.20               22                      Dead
              MP289              JAK2                  F           PV            61        265   140   no   98    42     0    no   3.3                  p.R213\* 3.29; p.I251T 0.93; p.Y234H 0.67                 39                      Alive
              MP273              JAK2                  F           ET            75        111   111   H    111    0     0    no   0.3                         p.C176S 0.31; p.S240G 0.22                         47                      Alive
              MP229              JAK2                  F           PMF           85        112   112   H    112    0     0    no   1.0                              c.376-1G\>A 0.95                              49                      Alive
              MP363              JAK2                  M           ET            87        117   112   H    112    0     0    no   0.3                                p.R248Q 0.29                                37                      Alive
               MP7               JAK2                  F           PV            69        133   130   H    121    9     0    no   0.5                                p.I255T 0.46                                64                      Alive
              MP329              JAK2                  F           ET            73        162   142   H    142    0     0    no   2.6                                p.R248W 2.61                                27                      Alive
              MP250              JAK2                  F           PV            74        152   152   H    152    0     0    no   0.4                                p.W91\* 0.36                                11                      Dead
               MP2               CALR                  F           ET            68        195   186   HA   169   11    110   no   11.6                        p.E286K 11.60; p.R248Q 0.45                        67                      Alive
              MP324              JAK2                  M           PV            72        255   255   H    255    0     0    no   0.3                                p.T253A 0.26                                15                      Dead

Abbreviations: A/ANG, anagrelide; B, busulphan; CH, chemotherapy; ET, essencial thrombocythemia; F, female; H/HU, hydroxyurea; I/IFN, interferon alpha; M, male; mo, months; PMF, primary myelofibrosis; PV, polycythemia vera; R, radiotherapy; y, years.

All three driver genes (*JAK2* V617F+exon 12*, CALR* exon 9 and *MPL* exon 10) were sequenced in all patients with *TP53* mutation.

Sample from leukemic transformation not available.

sAML *JAK2*-wt/*TP53*-wt.

Clonal expansion without leukemic transformation.

###### Clinical characteristics of patients according to *TP53* mutational status

                                                      *Treated (*N=*254)*   *Untreated (*N=*85)*                                                                                           
  --------------------------------------------------- --------------------- ---------------------- --------------------- ----- -------- ------------------- ----- ------------------ ----- ----
  N                                                   213                   100                    41                    100            76                  100   9                  100    
  Sex (male)                                          91                    43                     16                    39    NS       36                  47    5                  56    NS
  Age at study enrollment (median, range, s.d.)       62 (25--90, 13.2)                            69 (55--87, 7.4)            0.0002   70 (19--89, 13.8)         70 (66--82, 5.4)         NS
  Time from diagnosis (mo; median, range, s.d.)       109 (50--354, 54.9)                          111 (50--265, 54.5)         NS       0 (0--255, 52.9)          4 (0--53, 17.2)          NS
                                                                                                                                                                                           
  *Disease subtype*                                                                                                                                                                        
   ET                                                 67                    31                     13                    32    NS       21                  28    1                  11    NS
   PV                                                 96                    45                     20                    49             20                  26    2                  22     
   PMF                                                47                    22                     6                     15             30                  39    6                  67     
   unclassified MPN                                   3                     1                      2                     5              5                   7     0                  0      
   JAK2-mutated                                       157                   74                     33                    80    NS       54                  72    8                  89    NS
   JAK2-wt                                            56                    26                     8                     20             22                  29    1                  11     
   CALR-mut                                           37                    17                     7                     17             13                  17    1                  11     
   MPL-mut                                            7                     3                      1                     2              4                   5     0                  0      
   Triple negative                                    12                    6                      0                     0              3                   4     0                  0      
  *Therapetutic history*                                                                                                                                                                   
   Total therapy length (mo; median, range, s.d.)     87 (24--265, 44.7)                           92 (18--255, 45.4)          NS       0                         0                         
   HU yes                                             133                   62                     31                    76    NS       0                   0     0                  0      
   Length of HU in HU yes (mo; median, range, s.d.)   65 (2--265, 53.9)                            76 (17--255, 46.1)          0.0343   0                         0                         
   HU at study enrollment                             97                    46                     28                    68    0.0120   0                   0     0                  0      
   HU⩾48 months                                       94                    44                     28                    68    0.0060   0                   0     0                  0      
   ANG yes                                            95                    45                     9                     22    0.0392   0                   0     0                  0      
   IFN yes                                            72                    34                     12                    29    NS       0                   0     0                  0      
   Busulfan/chemo-/radiotherapy                       9                     4                      3                     7     NS       2                   3     1                  11    NS

Abbreviations: %, percentage of patients with given parameter in *TP53*-wt or *TP53*-mut group; mo, months; driver gene status considered in order *JAK2*\>*CALR*\>*MPL*; PMF, primary myelofibrosis; PV, polycythemia vera; ET, essential thrombocythemia; post-PV MF was grouped to PV, no post-PV patient carried TP53 mutation. *MPL* status was unknown in one untreated *JAK2*-wt/*CALR*-wt/*TP53*-wt patient

###### Monitoring *TP53* mutations over time

   *Sample ID*   *Retrospective (R) /prospective (P) analysis*   *First available sample: time from dg (y)*   *Study enrollment: time from dg (years)*   *Last available sample: time from dg (years)*   *Total follow-up (years)*   *MPN therapy before study enrollment*   *Therapy after study enrollment*   *Mutation* ⩾*0.1% in dg sample*    *The development of most abundant mutation (%)* [a](#t3-fn3){ref-type="fn"}    *Mutation development during follow-up*
  ------------- ----------------------------------------------- -------------------------------------------- ------------------------------------------ ----------------------------------------------- --------------------------- --------------------------------------- ---------------------------------- --------------------------------- ------------------------------------------------------------------------------- -----------------------------------------
      186A                             R                                            0.0                                         15.0                                         15.0                                  15.0                               IFN                     HU[b](#t3-fn4){ref-type="fn"}                   yes                                             0.4-**[8.3]{.ul}**-NA                                              Increase
      MP15                            P/R                                           0.2                                         7.0                                          11.9                                  11.5                             HU, IFN                                IFN                                no                            0-0.8-2.1-2.6-3.8-**[4.4]{.ul}**-10.7-11.3-11.2(W)13.8(G)                                 
      MP10                            P/R                                           0.0                                         6.4                                           9.8                                   9.8                               HU                                    HU                                no                                             0-**[10.1]{.ul}**-85.5                                                   
     JAK1716                          P/R                                           6.0                                         9.3                                          16.2                                  10.2                               IFN                                 IFN→HU                              NA                                     0-0.1-0.1-**[0.2]{.ul}**-0.7-2.2-2-2.2                                           
      MP326                           P/R                                           0.0                                         6.7                                           9.1                                   9.1                               HU                                    HU                                no                                            0-**[0.6]{.ul}**-0.5-0.5                                                  
      MP96                            P/R                                           0.0                                         5.4                                           8.8                                   8.8                               HU                                    HU                                no                                              0-**[0.5]{.ul}**-0.6                                                    
      MP168                           P/R                                           2.4                                         7.1                                          10.5                                   8.1                               HU                                    HU                                NA                                            0.1-**[1]{.ul}**-0.5-0.6                                                  
      MP319                           P/R                                           0.0                                         5.2                                           7.5                                   7.5                             HU, ANA                              HU, ANA                              yes                                          0.1-**[0.4]{.ul}**-0.4-0.8                                                 
      MP369                            P                                            0.0                                         0.0                                           7.0                                   7.0                 none[c](#t3-fn5){ref-type="fn"}                     HU                                NA                                             NA-**[0.13]{.ul}**-1.4                                                   
       65A                             P                                            13.2                                        13.2                                         19.6                                   6.5                            IFN, ANA                              IFN, ANA                             NA                                              NA-**[1.7]{.ul}**-5.4                                                   
      MP327                           P/R                                           4.9                                         10.4                                         11.2                                   6.3                               HU                                    HU                                NA                                            0-0.1-**[0.5]{.ul}**-0.5                                                  
      JAK22                            P                                            0.0                                         0.0                                           5.0                                   5.0                 none[c](#t3-fn5){ref-type="fn"}                     HU                                yes                                            NA-**[2.0]{.ul}**-46.1                                                   
      MP273                            P                                            9.3                                         9.3                                          12.0                                   2.8                               HU                                    HU                                NA                                           NA-**[0.3/0]{.ul}**-0.3/1.7                                                
      MP317                            P                                            5.5                                         5.5                                           6.0                                   0.5                               HU                                    HU                                NA                                              NA-**[0.8]{.ul}**-1.9                                                   
      MP289                           P/R                                           15.2                                        22.1                                         24.6                                   9.3                             HU, IFN                                none                               NA                  0.2/1.4-**[3.3/0.7]{.ul}**-4.4/0.4-6.3/0.6-3.5/0.4[d](#t3-fn6){ref-type="fn"}              Increase/decrease
      MP68                            P/R                                           0.0                                         4.8                                           8.3                                   8.3                             HU, ANA                              HU→none                              no                                   0-**[6.9]{.ul}**-8.8-10.7-11.7-16.9-9.6-2.7                                        
      MP315                           P/R                                           4.6                                         9.1                                          11.5                                   6.9                               IFN                                  IFN                                NA                                           0.2-**[0.8]{.ul}**-0.4-0.2                                                 
      MP230                            P                                            8.0                                         8.0                                           9.2                                   1.2                               HU                                    HU                                NA                                            NA-**[0.5]{.ul}**-2.3-1.3                                                 
      MP189                           P/R                                           6.9                                         11.5                                         14.6                                   7.7                               ANA                                HU, ANA                              NA                                                   3.9-2.8-2.5                                                    Stable
      MP155                           P/R                                           5.7                                         10.2                                         13.0                                   7.3                               ANA                                  ANA                                NA                                             0.4-**[0.2]{.ul}**-0.2                                                   
      MP229                            P                                            9.4                                         9.4                                          12.4                                   3.0                               HU                                 HU, ANA                              NA                                             NA-**[1]{.ul}**-0.5-0.6                                                  
      MP302                            P                                            19.3                                        19.3                                         21.7                                   2.4                           busulfan→HU                               HU                                NA                                            NA-**[0.4]{.ul}**-0.4-0.7                                                 
      MP329                            P                                            13.5                                        13.5                                         15.7                                   2.2                               HU                                 HU, ANA                              NA                                          NA-**[2.6]{.ul}**-1.9-3.1/3.0                                               
      MP324                            P                                            21.2                                        21.2                                         22.0                                   0.7                               HU                                    HU                                NA                                                   NA-0.3-0.4                                                         
      221A                            P/R                                           0.0                                         15.0                                         24.6                                  24.6                               IFN                                  IFN                                yes                         10.2/ND-**[2.2/0.6]{.ul}**-0.7/2.0[d](#t3-fn6){ref-type="fn"}                          Decrease
       MP2                            P/R                                           12.1                                        16.3                                         21.7                                   9.6                          HU, IFN, ANA                            HU, ANA                              NA                                    11.5-**[10.6]{.ul}**-11.6-2.9-2.2-1.9-2.1                                         
      MP63                            P/R                                           1.5                                         6.6                                          10.0                                   8.5                               HU                                    HU                                NA                           0-**[0.2/0.1]{.ul}**-0.1/0.2-0/0[d](#t3-fn6){ref-type="fn"}                                
      MP160                           P/R                                           1.2                                         5.1                                           7.1                                   5.8                               HU                                    HU                                NA                                              0.5-**[0.2]{.ul}**-0                                                    
      MP307                            P                                            8.6                                         8.6                                          10.2                                   1.6                               HU                                    HU                                NA                                                **[0.2]{.ul}**-0                                                      
      MP314                           P/R                                           14.8                                        19.4                                         21.9                                   7.1                           busulfan→HU                               HU                                NA                      3.3/0.2-**[1.3/0.4]{.ul}**-0.6/0.9-0.2/0.2[d](#t3-fn6){ref-type="fn"}                           
      MP345                           P/R                                           0.0                                         4.2                                           6.3                                   6.3                               HU                                    HU                                yes                                        0.1-**[1.1]{.ul}**-0.9-0.5-0.6                                               

Abbreviations: G, granulocytes; *NA*, not available; W, leukocytes.

Mutations with highest VAF are shown. \"Study enrollment\" describes the sampling from which the mutation was identified. For over-time monitoring and validation of previously identified mutation, cut-off 0.1% was applied (minimal coverage per base ⩾10000). VAF bellow 0.1% considered as a background (0%). Development was cathegorised as follows: increase---VAF twofold increase between first and last sample or no mutation at diagnosis; decrease---VAF decrease in VAF to half between first and last sample or no mutation at last sampling; increase/decrease---increase followed by decrease; stable---other. *y*, years; *NA*, not available; G, granulocytes; W, leukocytes.

Result from study enrollment is highlighted.

Samples not available.

Mutation identified at diagnosis.

Two mutations with the highest VAFs in distinct samplings.

[^1]: These authors contributed equally to this work.
